Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

Ameritas Advisory Services LLC increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 9.4% in ...

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024.

K-Bio leaders pursue U.S. factories and conferences during Lunar New Year K-Bio executives opt for international business ...

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

Bristol Myers Squibb will become responsible for the development and any marketing of DF6002 and its related products worldwide ... it plans to advance R&D in oncology and haematology and is ...

Overall, BMS reported a 2% rise in second-quarter revenues to $11.9 billion, led once again by Opdivo and anti-thrombotic drug Eliquis (apixaban) but backed by a series of new products that ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...